InSync in Circulation
This article was originally published in The Gray Sheet
Executive Summary
Medtronic Impedance Diagnostics in Heart Failure Trial results demonstrating the efficacy of OptiVol fluid status monitoring technology appear in Aug. 9 edition of Circulation, the Journal of the American Heart Association. Featured on Medtronic's InSync Sentry cardiac resynchronization defibrillator, OptiVol is "shown to provide a warning of fluid accumulation in some patients an average of 15 days before heart failure symptoms appeared and 18 days before hospital admission," according to an Aug. 9 release...